Somerset Therapeutics Recalls Dexamethasone Sodium Phosphate Injection Over Impurity Failures
Somerset Therapeutics, LLC has initiated a nationwide Class II recall (D-0398-2026) for 62,190 vials of Dexamethasone Sodium Phosphate Injection. The recall stems from out-of-specification impurity levels (EP impurity G and dexamethasone formate) detected during long-term stability testing at expiry. This event highlights critical quality control challenges for procurement and regulatory teams, necessitating immediate supply chain risk assessment for this essential corticosteroid.
FDA Class II Recall: Dexamethasone Sodium Phosphate Injection Fails Impurity Specifications
Somerset Therapeutics, LLC has initiated a voluntary, firm-initiated Class II recall, designated D-0398-2026, for its Dexamethasone Sodium Phosphate Injection, USP, 100 mg/ 10 mL (10 mg/mL). This critical action, reported on March 25, 2026, impacts 62,190 vials distributed nationwide across the United States. For procurement directors, this means an immediate assessment of existing inventory and orders is crucial to prevent supply gaps. The core issue, identified during long-term stability testing at the product's 24-month expiry, was out-of-specification (OOS) results for two specific impurities: Dexamethasone Sodium Phosphate EP impurity G (Impurity RU 49336) and dexamethasone formate. This failure to meet degradation specifications indicates a potential compromise in product quality over its shelf life. Regulatory affairs heads must ensure their organizations are fully compliant with recall procedures, including proper segregation and return of affected lot A240421, which carries an expiry date of July 31, 2026. A Class II classification signifies that the use of or exposure to the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This necessitates prompt action to protect patient safety and maintain regulatory standing.
Somerset Therapeutics' Operational Footprint and Recalled Product Profile
The recalling firm, Somerset Therapeutics, LLC, is based in Somerset, New Jersey, United States, operating from 300 Franklin Square Dr. This recall specifically targets their Dexamethasone Sodium Phosphate Injection, a human prescription drug administered via intramuscular or intravenous routes. The product is packaged as 10x10 mL Multiple Dose Vials, with NDC carton 70069-025-10 and NDC vial 70069-025-01. For business development executives, this event underscores the inherent risks in pharmaceutical manufacturing, even for established generic products. Dexamethasone Sodium Phosphate is a widely used corticosteroid, essential for its anti-inflammatory and immunosuppressant properties in various medical conditions. The recall of 62,190 vials of this critical injectable product, identified under ANDA211036, represents a significant disruption in the supply chain for healthcare providers relying on this specific formulation. Supply chain VPs must recognize that while the recall is firm-initiated and voluntary, the underlying quality control lapse reflects on the manufacturer's overall compliance posture. This incident mandates a review of supplier qualification processes, particularly concerning stability data and impurity profiles, to safeguard against similar future events impacting critical drug supplies.
Supply Chain Exposure: Mitigating Risks for Dexamethasone Sodium Phosphate Procurement
The nationwide distribution of 62,190 affected vials of Dexamethasone Sodium Phosphate Injection from Somerset Therapeutics, LLC, presents a tangible supply chain risk for procurement directors across the U.S. Healthcare systems, pharmacies, and distributors that have sourced this specific lot (A240421) must immediately quarantine and return the product. The Class II nature of this recall, while not indicating immediate life-threatening risk, still demands swift action to prevent potential patient exposure to substandard medication. For supply chain VPs, the immediate concern is ensuring continuity of supply for Dexamethasone Sodium Phosphate, a molecule critical in numerous therapeutic areas. This event highlights the vulnerability of relying heavily on a single supplier for essential generic injectables. Business development executives should monitor market dynamics closely, as this recall may create opportunities for alternative, compliant manufacturers to gain market share. Furthermore, regulatory affairs teams must be prepared to address any inquiries from healthcare providers or patients regarding the safety and availability of Dexamethasone Sodium Phosphate, reinforcing the need for transparent communication and robust recall management protocols.
Strategic Sourcing: Identifying Alternative Suppliers for Dexamethasone Sodium Phosphate
In light of Somerset Therapeutics' Dexamethasone Sodium Phosphate Injection recall, procurement teams must proactively identify and qualify alternative suppliers to maintain supply chain resilience. While specific alternative suppliers are not detailed in the available intelligence, the strategic imperative remains clear: diversify sourcing for critical generic molecules like Dexamethasone Sodium Phosphate. Supply chain VPs should initiate a comprehensive review of their approved vendor lists, prioritizing manufacturers with robust quality management systems and a proven track record of stability data compliance. The qualification process for a new pharmaceutical supplier, especially for an injectable product, can be lengthy, involving extensive audits, analytical testing, and potential regulatory filings (e.g., prior approval supplements for ANDAs). This timeline underscores the urgency of starting this process immediately. Geographic diversity in sourcing is also paramount, reducing reliance on a single region or facility and mitigating risks associated with localized disruptions. For business development executives, understanding the competitive landscape for Dexamethasone Sodium Phosphate and identifying potential partners or acquisition targets with strong quality profiles becomes a strategic advantage in a market impacted by quality events.
Broader Regulatory Context: Increasing Scrutiny on Pharmaceutical Quality Control
This recall by Somerset Therapeutics, LLC, occurs within a broader landscape of heightened FDA scrutiny on pharmaceutical quality control. Recent parallel events underscore a persistent industry challenge in maintaining stringent quality standards. For instance, Essential Wellness Pharma's Progesterone Injection faced a Class II recall due to sterility assurance failures, and Spectra Medical Devices' Lidocaine HCl Injection also experienced a Class II recall for similar deficiencies. Even non-sterility issues, such as metallic contamination leading to Guardian Drug Co. Inc.'s nationwide recall of Calcium Carbonate Antacids, or labeling deficiencies like Eugia US LLC's Class III recall of Lidocaine HCl Injection, reflect the FDA's active enforcement across various product categories. For regulatory affairs heads, these events collectively signal that the FDA is actively monitoring and enforcing compliance with current Good Manufacturing Practices (cGMP), particularly concerning product stability and impurity profiles. This trend means that companies must invest more in proactive quality assurance, robust stability programs, and comprehensive risk management strategies to avoid costly recalls and maintain market access. Procurement directors should factor this increased regulatory risk into their supplier selection and ongoing monitoring processes, favoring partners with demonstrably strong quality systems.